PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma
Cells, 2021 The dependence of cancer on an immunotolerant tumor microenvironment (TME) is well established. Immunotherapies that overcome tumor-induced immune suppression have been central to recent advancements in oncology.
Joshua W. D. Tobin +3 more
doaj +1 more source
The Role of Palliative Surgery for Malignant Bowel Obstruction and Perforation in Advanced Microsatellite Instability-High Colorectal Carcinoma in the Era of Immunotherapy: Case Report. [PDF]
, 2020 The role of palliative surgery in the management of acute complications in patients with disseminated malignancy remains controversial given the complexity of assessing acute surgical risk and long-term oncologic outcome. With the emergence of checkpoint
Bold, Richard J +13 more
core
The Evolving Role of CD8+CD28- Immunosenescent T Cells in Cancer Immunology [PDF]
, 2019 Functional, tumor-specific CD8+ cytotoxic T lymphocytes drive the adaptive immune response to cancer. Thus, induction of their activity is the ultimate aim of all immunotherapies.
Dey, Mahua +4 more
core +1 more source
DISSECTION OF T CELL ACTIVATION PHASES FOR CHECK POINT BLOCKADE IMMUNOTHERAPY
Sabiad, 2022 Checkpoint blockade immunotherapy relies on the restoration of effector responses in precursor-exhausted T cells. Nevertheless, many inhibitory receptors are upregulated soon after the activation and reach high levels at effector phases.
Güneş Esendağlı
doaj +1 more source
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy [PDF]
, 2017 Immune checkpoint factors, such as programmed cell death protein-1/2 (PD-1, PD-2) or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptors, are targets for monoclonal antibodies (MAbs) developed for cancer immunotherapy.
Mai, Antonello +3 more
core +1 more source
Renal complications of immune checkpoint blockade [PDF]
Current Problems in Cancer, 2017 Immune checkpoint inhibitors have been approved for a variety of cancer species. Renal complications in use of these agents are not very common compared with other immune-related adverse events (irAE). However, it is crucial for physicians to recognize and manage renal manifestations of irAE.
Naoka, Murakami +2 more
openaire +2 more sources
HDAC inhibition potentiates immunotherapy in triple negative breast cancer. [PDF]
, 2017 Triple-negative breast cancer (TNBC) represents a more aggressive and difficult subtype of breast cancer where responses to chemotherapy occur, but toxicity is significant and resistance often follows. Immunotherapy has shown promising results in various
Ali, Niwa +8 more
core +1 more source
Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. [PDF]
, 2020 Although immunotherapies have achieved remarkable salutary effects among subgroups of advanced cancers, most patients do not respond. We comprehensively evaluated biomarkers associated with the "cancer-immunity cycle" in the pan-cancer setting in order ...
Dressman, Devin +13 more
core +1 more source
Smoldering myocarditis following immune checkpoint blockade [PDF]
Journal for ImmunoTherapy of Cancer, 2017 Severe myocarditis associated with electrical conduction abnormalities and occasionally heart failure has been well documented following treatment with immune checkpoint blockade with an estimated incidence of less than 1%. However, the incidence, early detection, and management of less severe immune-related myocarditis are unknown since most ...
Timothy G. Norwood +8 more
openaire +5 more sources
Frontiers in Immunology, 2017 Immune checkpoint inhibitors, which target coinhibitory T cell molecules to promote anticancer immune responses, are on the rise to become a new pillar of cancer therapy.
Carmen Stecher +7 more
doaj +1 more source